| Original language | English (US) |
|---|---|
| Pages (from-to) | 124-127 |
| Number of pages | 4 |
| Journal | Annals of Allergy, Asthma and Immunology |
| Volume | 120 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2018 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Pulmonary and Respiratory Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Annals of Allergy, Asthma and Immunology, Vol. 120, No. 2, 02.2018, p. 124-127.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - The importance of reducing risk in peanut allergy
T2 - Current and future therapies
AU - Shreffler, Wayne G.
AU - Baumert, Joe L.
AU - Remington, Benjamin C.
AU - Koppelman, Stef J.
AU - Dinakar, Chitra
AU - Fleischer, David M.
AU - Kim, Edwin
AU - Tilles, Stephen A.
AU - Spergel, Jonathan M.
N1 - Funding Information: Disclosures: All authors participated in a recent advisory board meeting sponsored by DBV Technologies during which discussion on relative risk reduction in peanut allergy brought up the need for more communication and education on this important concept. Dr Shreffler reported working as a consultant for DBV Technologies and Sanofi and receiving grant support from DBV Technologies, Aimmune Therapeutics, the National Institutes of Health, and Food Allergy Research Education (FARE). Dr Baumert reported working as a consultant for DBV Technologies. Dr Koppelman reported working as a consultant for DBV Technologies. Dr Dinakar reported working as a consultant for DBV Technologies and FARE and receiving grant support from DBV Technologies, Aimmune Therapeutics, and FARE. Dr Fleischer reported working as a consultant for and receiving grant support from DBV Technologies. Dr Kim reported receiving honoraria from DBV Technologies and Aimmune Therapeutics. Dr Tilles reported working as a consultant for DBV Technologies, Aimmune Therapeutics, and FARE and receiving grant support from DBV Technologies, Aimmune Therapeutics, and FARE. Dr Spergel reported working as a consultant for DBV Technologies, FARE, and Regeneron and receiving grant support from DBV Technologies, Aimmune Therapeutics, the National Institutes of Health, and FARE. No other disclosures were reported. Funding Information: Funding Sources: Editorial support was provided by IMPRINT Science , New York, New York, and funded through an unrestricted grant provided by DBV Technologies .
PY - 2018/2
Y1 - 2018/2
UR - http://www.scopus.com/inward/record.url?scp=85044852642&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044852642&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2017.10.038
DO - 10.1016/j.anai.2017.10.038
M3 - Article
C2 - 29289463
AN - SCOPUS:85044852642
SN - 1081-1206
VL - 120
SP - 124
EP - 127
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 2
ER -